ArticleJournal of assisted reproduction and genetics2025
Inhibition of integrated stress response by ISRIB promotes mouse and human primordial follicle activation via the mTOR pathway.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin B6 promotes the activation of primordial follicles through the PI3K/Akt signaling pathway.Journal of ovarian research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThe aim of this study is to investigate the effect of integrated stress response (ISR) inhibitor (ISRIB) on primordial follicle activation.
methodsWe identified drugs promoting primordial follicle activation and investigated their mechanisms through culturing newborn mouse ovaries in vitro. Validation was performed in vivo through intraperitoneal injection in newborn mice. Additionally, we analyzed its potential mechanisms through transcriptome sequencing. Finally, the function and mechanisms of ISRIB were further validated through culturing human ovarian tissues in vitro.
resultsISR activity was present in neonatal mouse ovaries. ISRIB in vitro culture and in vivo intraperitoneal injection significantly decreased the protein levels of phosphorylated eukaryotic translation initiation factor 2 subunit alpha (p-eIF2α) and activating transcription factor 4 (ATF4). ISRIB also significantly increased the growing follicle number and the protein levels of phosphorylated mammalian target of rapamycin (p-mTOR), KIT ligand (KITL), phosphorylated protein kinase B (p-Akt), and phosphorylated forkhead Box O3a (p-FOXO3a) in neonatal mouse ovaries and/or cultured human ovarian fragments. ISRIB significantly increased the relative fluorescence intensities of p-mTOR in the pre-granulosa cells of primordial follicles, and ISRIB-induced increase of p-Akt and p-FOXO3a was completely reversed by KIT inhibitor ISCK03. In the excessive ISR mouse model induced by corticosterone, ISRIB could partially reverse the apoptosis of primordial and growing follicles.
conclusionISRIB promoted mouse and human primordial follicle activation via the mTOR pathway and partly reversed corticosterone-induced decrease of growing follicles. These results suggest that ISRIB may be a potential drug for rescuing infertility in POI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.